WuXi Apptec

Historical price data

WuXi AppTec is a premier global pharmaceutical CRDMO that enables innovation through its integrated platform spanning chemistry drug CRDMO, biology discovery, preclinical testing, and clinical research services. Founded in 2000 and guided by the vision that 'every drug can be made and every disease can be treated,' the company has grown from 4 co-founders to a global enterprise with 38,000+ employees. WuXi AppTec has been recognized by Frost & Sullivan as Global Company of the Year in the CRDMO industry for nine consecutive years and maintains the highest sustainability ratings. The company is expanding its global footprint with recent strategic partnerships in Saudi Arabia and continues to demonstrate strong financial performance with double-digit growth.

Integrated CRDMO platform providing end-to-end pharmaceutical services spanning chemistry drug CRDMO, biology discovery, preclinical testing, and clinical research services. The platform integrates CMC, Pharmacology, DMPK, Toxicology, and Bioanalysis services to support drug development from discovery through commercial manufacturing.

Total raised: $194.1M

WuXi AppTec competes against major players including Catalent, Lonza, PPD/Thermo Fisher, IQVIA, and Charles River Laboratories, differentiating itself through its integrated CRDMO model, global footprint, and scale with 38,000+ employees. The company has maintained market leadership with nine consecutive years of Frost & Sullivan's Global Company of the Year recognition in the CRDMO industry.